LNC vs URGN · P/E 4.9, rev $9.85B vs rev $109.8M
Lincoln National Corporation (LNC) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Lincoln National Corporation (LNC) is a insurance - life company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported LNC revenue for 2026-06-30 was $9.85B. Net income was $1.16B. Revenue was up 85.6% from 2026-03-31 to 2026-06-30. LNC currently screens at market cap $5.94B and trailing P/E 4.9.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
LNC currently screens at market cap $5.94B and trailing P/E 4.9. URGN currently screens at market cap $1.61B.
Not investment advice. Open the LNC and URGN stock pages for the full models.
Not investment advice.